Mirati Therapeutics (MRTX) News Today → Move Your Money Before May 22 (From Stansberry Research) (Ad) Free MRTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineMirati Therapeutics (NASDAQ:MRTX) Earns Sell Rating from Analysts at StockNews.commarketbeat.com - January 30 at 1:20 AMAssenagon Asset Management S.A. Boosts Stock Holdings in Mirati Therapeutics, Inc. (NASDAQ:MRTX)marketbeat.com - January 25 at 6:23 PMmarketbeat.com - January 23 at 6:00 AMMirati Therapeutics, Inc. (NASDAQ:MRTX) EVP Benjamin Hickey Sells 1,597 Sharesmarketbeat.com - January 18 at 7:24 PMTD Asset Management Inc Grows Position in Mirati Therapeutics, Inc. (NASDAQ:MRTX)marketbeat.com - January 16 at 5:43 AMMirati Therapeutics, Inc. (NASDAQ:MRTX) Sees Large Decline in Short Interestmarketbeat.com - January 12 at 10:51 AMMirati Therapeutics Receives Marketing Authorization For KRAZATI From European Commissionmarkets.businessinsider.com - January 10 at 1:33 PMEuropean Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutationfinance.yahoo.com - January 10 at 8:33 AMMirati Therapeutics, Inc. (NASDAQ:MRTX) Receives Average Recommendation of "Hold" from Analystsmarketbeat.com - January 10 at 2:52 AMMirati Therapeutics, Inc. (NASDAQ:MRTX) EVP Sells $123,142.80 in Stockmarketbeat.com - January 9 at 6:48 PMInsider Selling: Mirati Therapeutics, Inc. (NASDAQ:MRTX) EVP Sells 1,531 Shares of Stockmarketbeat.com - January 5 at 7:02 PMMirati Therapeutics, Inc. (NASDAQ:MRTX) Stock Position Reduced by Handelsbanken Fonder ABmarketbeat.com - January 5 at 4:38 AMSG Americas Securities LLC Buys 25,335 Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX)marketbeat.com - December 28 at 4:53 AMEvaluating Mirati Therapeutics' CVR Value In The Wake Of The Bristol Myers Acquisitionseekingalpha.com - December 25 at 5:42 AMBristol Myers to buy schizophrenia drugmaker Karuna Therapeutics for $14 blnreuters.com - December 22 at 1:49 PMKaruna Therapeutics soars after $14 billion takeover by Bristol Myersmsn.com - December 22 at 8:49 AMCitigroup Downgrades Mirati Therapeutics (MRTX)msn.com - December 20 at 10:03 PMMirati Therapeutics Inc EVP & Chief Scientific Officer Jamie Christensen Sells 2,387 Sharesfinance.yahoo.com - December 20 at 12:01 PMMirati Therapeutics (NASDAQ:MRTX) Stock Rating Reaffirmed by Citigroupmarketbeat.com - December 20 at 8:17 AMInsider Sell Alert: EVP Benjamin Hickey Sells Shares of Mirati Therapeutics Inc (MRTX)finance.yahoo.com - December 15 at 7:36 AMMirati Therapeutics Inc MRTXmorningstar.com - December 12 at 9:21 PMBillionaire Joe Lewis Keeps Trading Stocks Behind US Insider-Trading Chargesfinance.yahoo.com - December 12 at 9:29 AMMirati Therapeutics, Inc. (NASDAQ:MRTX) Shares Sold by Braidwell LPmarketbeat.com - December 11 at 9:17 AMCamber Capital Management LP Buys 400,000 Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX)marketbeat.com - December 10 at 10:27 AMCasdin Capital LLC Reduces Stock Holdings in Mirati Therapeutics, Inc. (NASDAQ:MRTX)marketbeat.com - December 8 at 11:13 AMMirati Therapeutics Stock (NASDAQ:MRTX), Short Interest Reportbenzinga.com - December 3 at 10:11 AMMirati Therapeutics Stock (NASDAQ:MRTX) Dividends: History, Yield and Datesbenzinga.com - December 3 at 10:11 AMMoore Kuehn Encourages PCTI, MRTX, CSTR, and BBAI Investors to Contact Law Firmbenzinga.com - November 15 at 3:21 PMMirati Therapeutics Gets CHMP Backing for Krazatimarketwatch.com - November 10 at 10:14 AMMirati's lung cancer drug gets EU's regulatory backingreuters.com - November 10 at 10:14 AMUPDATE 1-Mirati's lung cancer drug gets EU's regulatory backingfinance.yahoo.com - November 10 at 10:14 AMLeerink Partners Downgrades Mirati Therapeutics (MRTX)msn.com - November 8 at 10:04 AMStifel Downgrades Mirati Therapeutics (MRTX)msn.com - November 8 at 10:04 AMParamount slashed 2 notches to sell; Ameresco in free fall: 5 big analyst cutsfinance.yahoo.com - November 7 at 9:01 AMMirati Therapeutics Inc (MRTX) Reports Q3 2023 Financial Resultsfinance.yahoo.com - November 6 at 4:20 PMMirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updatesfinance.yahoo.com - November 6 at 8:39 AMMirati Gets MHRA Approval for Krazati to Treat Non-Small Cell Lung Cancer Patientsmarketwatch.com - November 3 at 7:35 PMKura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLCfinance.yahoo.com - November 2 at 8:47 AMMirati Therapeutics (MRTX) Price Target Increased by 16.97% to 64.71msn.com - November 2 at 12:34 AMMirati Therapeutics Inc (26M.BE)finance.yahoo.com - October 26 at 6:25 AMHold Rating on Mirati Therapeutics: A Comparative Analysis with Amgen and Future Prospectsmarkets.businessinsider.com - October 18 at 8:54 AMPiper Sandler Downgrades Mirati Therapeutics (MRTX)msn.com - October 12 at 10:26 AMMirati Therapeutics Falls 5% After Bristol Myers Squibb Decides To Acquire Itmarkets.businessinsider.com - October 11 at 1:29 AMMirati (MRTX) Gets Buyout Offer From Bristol Myers for $4.8Bfinance.yahoo.com - October 11 at 1:29 AMMirati Therapeutics: Anatomy Of A Long Simmering Buyoutmsn.com - October 10 at 3:28 PMMIRATI THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati ...businesswire.com - October 9 at 6:23 PMMirati Therapeutics could see another bidder emerge, Leerink saysmsn.com - October 9 at 1:22 PMShareholder Alert: Ademi LLP investigates whether Mirati Therapeutics, Inc. has obtained a Fair Price in its transaction with Bristol Myers Squibbbenzinga.com - October 9 at 8:22 AMMRTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Mirati Therapeutics, Inc. Is Fair to Shareholdersbusinesswire.com - October 8 at 9:01 PMBristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billionmarketwatch.com - October 8 at 8:02 PM Get Mirati Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Move Your Money Before May 22 (Ad)The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. MRTX Media Mentions By Week MRTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MRTX News Sentiment▼0.000.32▲Average Medical News Sentiment MRTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MRTX Articles This Week▼04▲MRTX Articles Average Week Get Mirati Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ALKS News Today PRGO News Today ALPN News Today NUVL News Today MDGL News Today BBIO News Today CBAY News Today RARE News Today INSM News Today PBH News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MRTX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirati Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
